Effects of an Intervention Initiated by a National Society to Improve Postabortion Care in Rural Facilities in Burkina Faso

Int J Gynaecol Obstet. 2017 Feb;136(2):215-219. doi: 10.1002/ijgo.12031. Epub 2016 Nov 24.

Abstract

Objective: To evaluate the results of an intervention by the Societé de Gynécologues et Obstétriciens du Burkina (SOGOB) to improve postabortion care (PAC) in rural areas of Burkina Faso.

Methods: From June 1, 2012, to May 31, 2013, SOGOB increased capacity for PAC by providing training in health care and equipment to 45 rural health facilities. Performance in PAC in the year before intervention (June 1, 2011, to May 31, 2012) was compared with that in the year following intervention (June 1, 2013, to May 31, 2014).

Results: The number of cases of incomplete abortion managed within a year increased from 1812 before the intervention to 2738 afterwards. Before capacity building, none of the health facilities was using misoprostol for management of incomplete abortion. After capacity building, misoprostol was used in 805 (29.4%) cases. The use of inappropriate methods to empty the uterus decreased (27.5% [498/1812] vs 1.4% [38/2738]; P<0.001). The frequencies of uterine perforation and pelvic infection also decreased (P≤0.01 for both). In the year after implementation, 2035 (78.3%) of 2600 women had taken up a family planning method before leaving the facility.

Conclusion: SOGOB's intervention has improved the quality of PAC in rural health facilities in Burkina Faso.

Keywords: Burkina Faso; Family planning; Misoprostol; Postabortion care.

MeSH terms

  • Abortifacient Agents, Nonsteroidal / administration & dosage*
  • Abortion, Incomplete / drug therapy*
  • Abortion, Incomplete / epidemiology
  • Adult
  • Aftercare / standards*
  • Burkina Faso
  • Family Planning Services / statistics & numerical data
  • Female
  • Health Facilities / supply & distribution*
  • Health Personnel / education*
  • Humans
  • Misoprostol / administration & dosage*
  • Pregnancy
  • Rural Population
  • Societies, Medical

Substances

  • Abortifacient Agents, Nonsteroidal
  • Misoprostol